Novaliq GmbH

Novaliq GmbH is a German pharmaceutical company founded in 2007. It specializes in the development and commercialization of ocular therapeutics using EyeSol®, the first water-free technology for ophthalmology products. With a focus on addressing the unmet medical needs of millions of patients with eye disease, particularly dry eye disease (DED), Novaliq boasts an industry-leading portfolio. The company's late-stage development compounds, NOV03 and CyclASol®, have shown superior clinical benefits in treating evaporative DED associated with meibomian gland dysfunction and aqueous deficient DED, respectively. NovaTears®, their water-free eye drops, are CE certified and commercialized in various regions. Headquartered in Heidelberg, Germany, Novaliq also has an office in Cambridge, MA, USA. Novaliq's recent €13.90M Venture Round investment on 12 April 2022 was backed by notable investors including SAP and the long-term shareholder, dievini Hopp Biotech Holding, known for active investments in the Life and Health Sciences sector. With a strong emphasis on transforming ocular therapeutics, Novaliq is poised for further growth and innovation in the Biotechnology, Health Care, and Pharmaceutical industries.